You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Reasons for antiretroviral modification among HIV patients on HAART

From: Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia

  1 2 3 4 5 6 Total
Drug out of stock 0(0.00) 0(0.00) 3(5.56) 0 (0.00) 0 (0.00) 0(0.00) 3(0.48)
Hepatitis 0(0.00) 0(0.00) 1 (1.85) 0 (0.00) 0(0.00) 0(0.00) 1(0.16)
New TB 68(16.35) 3(3.00) 15 (27.78) 0 (0.00) 1(5.88) 1(25.00) 88(14.31)
Phaseout 106(25.48) 18 (18.00) 0(0.00) 0 (0.00) 0(0.00) 0(0.00) 124(20.16)
Pregnancy 1(2.40) 6 (6.00) 0 (0.00) 5 (20.83) 11(64.70) 1(25.00) 24(3.9)
Toxicity/side effect 198(47.59) 56(56.00) 29 (53.70) 13 (54.17) 3(17.65) 2(50.00) 301(48.94)
Treatment failure 2(4.1) 1 (1.00) 1 (1.85) 0 (0.00) 0 (0.00) 0(0.00) 4(0.65)
unknown 41 (9.86) 16 (16.00) 5 (9.26) 6 (25.00) 2 (11.76) 0(0.00) 70(11.38)
Total change 416 100 54 24 17 4 615
  1. Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP